X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

HPAPI Market Witnesses A Surge Globally With A CAGR of 8.6%

Content Team by Content Team
16th February 2023
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

As per a market report by Reportlinker, the worldwide highly potent active pharmaceutical ingredient- HPAPI sector is anticipated to breach the $34.04 billion mark by 2026 at a CAGR of around 8.5%.

HPAPIs are substances that cause a biological response even at extremely low doses.It is well to be noted that cytotoxic substances as well as sex hormones such as oestrogen are considered as significant examples of HPAPIs.

Apparently, last year, it was North America that happened to be the biggest market for HPAPI. The middle east as per the report is expected to be the fastest growing region in the forecast period.

Factors that Influence the HPAPI Market

The report has observed that the inflation caused by the recent war has led to economic sanctions on goods and services across multiple nations. This has gone on to increase the prices of commodities as well as supply chain disruptions.

With increasing number of cancer cases, research has found that the surge in cancer drug sales has contributed to the growth of the HPAPI market. The rising cancer incidences have resulted in more R&D on anticancer drugs, hence propelling the demand for HPAPIs.

As per a report by the International Agency for Research on Cancer and the World Health Organization, the burden of cancer is expected to surge by 29.5 million new cases and around 16.4 million deaths by 2040 around the world. Because of the growing instances of cancer cases, the HPAPI market is going to have an upsurge in revenues. The report states that firms are planning on strategies to expand their existing production facilities as well as go ahead with mergers and acquisitions so as to maintain their position in the market.

A new $65 million facility that was opened in the US last year in June to exclusively manufacture HPAPIs with a cancer treatment emphasis is a significant example in this regard.

Challenges in the manufacturing of HPAPIs

These substances come with prominent handling challenges, including specialised equipment requirements so as to avoid incidences of cross-contamination and also ensure operator and environment safety. Besides, the appropriate process design need, continuous tech evolution and industry benchmarks, and exclusively specialised containment facilities in order to maintain the safety of employees mean that a large amount of investment is needed, which is one of the factors hindering the growth of the HPAPI market.

Previous Post

Cancer Vaccine Transformation - A Possibility Soon To Occur

Next Post

Clinical Trials Diversity - A Much To Be Explored Segment

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post

Clinical Trials Diversity - A Much To Be Explored Segment

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In